Enovis Corp (ENOV)

Currency in USD
27.25
+2.40(+9.66%)
Closed·
27.50+0.25(+0.92%)
·
ENOV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
24.9527.75
52 wk Range
21.0037.85
Key Statistics
Prev. Close
27.25
Open
25.14
Day's Range
24.95-27.75
52 wk Range
21-37.85
Volume
1.94M
Average Volume (3m)
973.67K
1-Year Change
-17.6239%
Book Value / Share
26.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENOV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.64
Upside
+60.13%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price movements are quite volatile

Enovis Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 43.64
(+60.13% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
William Blair
Buy---New CoverageApr 17, 2026
BTIG
Buy39.00+43.12%43.00MaintainApr 13, 2026
Evercore ISI
Buy35.00+28.44%36.00MaintainApr 06, 2026
UBS
Buy50.00+83.49%50.00MaintainMar 18, 2026
Needham
Buy52.00+90.83%49.00MaintainFeb 26, 2026

Enovis Corp Earnings Call Summary for Q1/2026

  • Enovis Q1 2026 EPS of $0.89 beat estimates by 9.88%; revenue hit $589M, exceeding forecasts by 2.79%, driving shares up 4.23% to $25.90.
  • Reconstruction segment led with 6% organic growth (days-adjusted); company posted 5% YoY revenue growth and 62% adjusted gross margin, up 40bps.
  • CEO McDonald emphasized innovation strategy with ARVIS system adoption; company reaffirmed 2026 guidance with revenues split evenly between halves.
  • Free cash flow conversion projected to exceed 25% for 2026; extremities and hip markets expected to drive continued growth throughout the year.
  • Key risks include supply chain disruptions, tariff pressures on Prevention & Recovery segment, and macroeconomic uncertainties affecting global demand.
Last Updated: 2026/05/07, 18:18
Read Full Transcript

Earnings

Latest Release
May 07, 2026
EPS / Forecast
0,89 / 0,81
Revenue / Forecast
589M / 573,02M
EPS Revisions
Last 90 days

ENOV Income Statement

Compare ENOV to Peers and Sector

Metrics to compare
ENOV
Peers
Sector
Relationship
P/E Ratio
−1.3x−7.5x−0.6x
PEG Ratio
0.03−1.420.00
Price/Book
1.1x3.1x2.6x
Price / LTM Sales
0.7x2.6x3.2x
Upside (Analyst Target)
81.1%46.5%48.1%
Fair Value Upside
Unlock15.0%5.8%Unlock

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
35,09M60,99%956,24M
Other Institutional Investors
31,52M39,01%858,99M
Public Companies & Retail Investors
0,000,00%0,00
Total
66,61M100,00%1,82B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15,48%8 906 305242 697
The Vanguard Group, Inc.11,19%6 438 598175 452

FAQ

What Is the Enovis (ENOV) Stock Price Today?

The Enovis stock price today is 27,25 USD.

What Stock Exchange Does Enovis Trade On?

Enovis is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Enovis?

The stock symbol for Enovis is "ENOV."

What Is the Enovis Market Cap?

As of today, Enovis market cap is 1,57B USD.

What Is Enovis's Earnings Per Share (TTM)?

The Enovis EPS (TTM) is -19,88.

When Is the Next Enovis Earnings Date?

Enovis will release its next earnings report on Jul 30, 2026.

From a Technical Analysis Perspective, Is ENOV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Enovis Stock Split?

Enovis has split 1 times.

How Many Employees Does Enovis Have?

Enovis has 7802 employees.

What is the current trading status of Enovis (ENOV)?

As of May 08, 2026, Enovis (ENOV) is trading at a price of 27,25 USD, with a previous close of 27,25 USD. The stock has fluctuated within a day range of 24,95 USD to 27,75 USD, while its 52-week range spans from 21,00 USD to 37,85 USD.

What Is Enovis (ENOV) Price Target According to Analysts?

The average 12-month price target for Enovis is 43,64 USD, with a high estimate of 55 USD and a low estimate of 33 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +60,13% Upside potential.

What Is the ENOV After Hours Price?

ENOV's last after hours stock price is 27,50 USD, the stock has decreased by 0,25, or 0,92%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.